| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2388 | 2019 |
| PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma MR Migden, D Rischin, CD Schmults, A Guminski, A Hauschild, KD Lewis, ... New England Journal of Medicine 379 (4), 341-351, 2018 | 1297 | 2018 |
| Targeted therapy for non-small cell lung cancer: current standards and the promise of the future BA Chan, BGM Hughes Translational lung cancer research 4 (1), 36, 2015 | 838 | 2015 |
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study SHI Ou, JS Ahn, L De Petris, R Govindan, JCH Yang, B Hughes, H Lena, ... Journal of clinical oncology 34 (7), 661-668, 2016 | 715 | 2016 |
| Evaluation of circulating tumor cells and circulating tumor DNA in non–small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab … EA Punnoose, S Atwal, W Liu, R Raja, BM Fine, BGM Hughes, RJ Hicks, ... Clinical Cancer Research 18 (8), 2391-2401, 2012 | 510 | 2012 |
| Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ... Cancer discovery 10 (1), 40-53, 2020 | 247 | 2020 |
| Quality-of-life among head and neck cancer survivors at one year after treatment–a systematic review WKW So, RJ Chan, DNS Chan, BGM Hughes, SY Chair, KC Choi, ... European journal of cancer 48 (15), 2391-2408, 2012 | 210 | 2012 |
| Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629) JJ Grob, R Gonzalez, N Basset-Seguin, O Vornicova, J Schachter, A Joshi, ... Journal of Clinical Oncology 38 (25), 2916, 2020 | 205 | 2020 |
| Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma MC Foote, M McGrath, A Guminski, BGM Hughes, J Meakin, D Thomson, ... Annals of oncology 25 (10), 2047-2052, 2014 | 165 | 2014 |
| KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G De Castro, ... Annals of Oncology 29, viii729, 2018 | 164 | 2018 |
| Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study KJ Harrington, B Burtness, R Greil, D Soulières, M Tahara, G de Castro Jr, ... Journal of Clinical Oncology 41 (4), 790-802, 2023 | 150 | 2023 |
| Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing D Rischin, MR Migden, AM Lim, CD Schmults, NI Khushalani, ... Journal for immunotherapy of cancer 8 (1), 2020 | 150 | 2020 |
| Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell … D Rischin, KJ Harrington, R Greil, D Soulieres, M Tahara, G de Castro, ... Journal of Clinical Oncology 37 (15_suppl), 6000-6000, 2019 | 148 | 2019 |
| Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C J Bromley, BGM Hughes, DCS Leong, NA Buckley Annals of pharmacotherapy 39 (9), 1566-1569, 2005 | 142 | 2005 |
| Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma ND Gross, DM Miller, NI Khushalani, V Divi, ES Ruiz, EJ Lipson, F Meier, ... New England Journal of Medicine 387 (17), 1557-1568, 2022 | 139 | 2022 |
| Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non–small cell lung cancer treated with erlotinib L Mileshkin, RJ Hicks, BGM Hughes, PLR Mitchell, V Charu, BJ Gitlitz, ... Clinical Cancer Research 17 (10), 3304-3315, 2011 | 136 | 2011 |
| Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in AK Nowak, WJ Lesterhuis, PS Kok, C Brown, BGM Hughes, DJ Karikios, ... The Lancet Oncology 21 (9), 1213-1223, 2020 | 135 | 2020 |
| Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial BGM Hughes, E Munoz-Couselo, L Mortier, Å Bratland, R Gutzmer, ... Annals of Oncology 32 (10), 1276-1285, 2021 | 116 | 2021 |
| Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death ligand-1 combined … B Burtness, D Rischin, R Greil, D Soulières, M Tahara, G de Castro Jr, ... Journal of Clinical Oncology 40 (21), 2321-2332, 2022 | 113 | 2022 |
| CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells M Braun, AR Aguilera, A Sundarrajan, D Corvino, K Stannard, S Krumeich, ... Immunity 53 (4), 805-823. e15, 2020 | 98 | 2020 |
Danny RischinPeter MacCallum Cancer Centre在 petermac.org 的电子邮件经过验证
